Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

P. Hillemanns, M. Zikan, F. Forget, HG. Denys, JF. Baurain, L. Rob, L. Woelber, P. Blecharz, M. Bidzinski, J. Chovanec, F. Marmé, T. Link, C. Dannecker, A. Rosholm, KCG. Berg, RS. Oliveri, K. Lindemann, VB C-02 investigators, VB C-02 study

. 2025 ; 13 (1) : . [pub] 20250107

Language English Country England, Great Britain

Document type Journal Article, Clinical Trial, Phase II, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25010322

BACKGROUND: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer. PATIENTS AND METHODS: This multicenter, single-arm, phase 2a study (NCT04405349, registered 26 May 2020) enrolled adult patients with persistent, r/m HPV16-positive cervical cancer. Patients received 3 mg VB10.16 (every 3 weeks (Q3W) for 12 weeks, hereafter every 6 weeks) combined with 1,200 mg atezolizumab (Q3W) for 48 weeks in total with a 12-month follow-up. The primary endpoints were incidence and severity of adverse events (AEs) and objective response rate (ORR; Response Evaluation Criteria in Solid Tumor V.1.1). ORR was assessed in the efficacy population, being all response-evaluable patients who received any administration of VB10.16 and atezolizumab and had at least one post-baseline imaging assessment. RESULTS: Between June 16, 2020, and January 25, 2022, 52 patients received at least one administration of study treatment. Of these, 47 patients had a minimum of one post-baseline tumor assessment. The median follow-up time for survival was 11.7 months. AEs related to VB10.16 were non-serious and mainly mild injection site reactions (9 of 52 patients). There were no signs of new toxicities other than what was already described with atezolizumab. ORR was 19.1% (95% CI 9.1% to 33.3%). Median duration of response was not reached (n.r.) (95% CI 2.2 to n.r.), median progression-free survival was 4.1 months (95% CI 2.1 to 6.2), and median overall survival was 21.3 months (95% CI 8.5 to n.r.). In programmed death-ligand 1 (PD-L1)-positive patients (n=24), ORR was 29.2% (95% CI 12.6 to 51.1). HPV16-specific T-cell responses were analyzed in 36 of 47 patients with an increase observed in 22/36 (61%). CONCLUSIONS: The therapeutic DNA-based vaccine VB10.16 combined with atezolizumab was safe and well tolerated showing a promising clinically meaningful efficacy with durable responses in patients with persistent, r/m HPV16-positive cervical cancer, especially if PD-L1-positive.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010322
003      
CZ-PrNML
005      
20250429135503.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jitc-2024-010827 $2 doi
035    __
$a (PubMed)39773564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hillemanns, Peter $u Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany
245    10
$a Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study / $c P. Hillemanns, M. Zikan, F. Forget, HG. Denys, JF. Baurain, L. Rob, L. Woelber, P. Blecharz, M. Bidzinski, J. Chovanec, F. Marmé, T. Link, C. Dannecker, A. Rosholm, KCG. Berg, RS. Oliveri, K. Lindemann, VB C-02 investigators, VB C-02 study
520    9_
$a BACKGROUND: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer. PATIENTS AND METHODS: This multicenter, single-arm, phase 2a study (NCT04405349, registered 26 May 2020) enrolled adult patients with persistent, r/m HPV16-positive cervical cancer. Patients received 3 mg VB10.16 (every 3 weeks (Q3W) for 12 weeks, hereafter every 6 weeks) combined with 1,200 mg atezolizumab (Q3W) for 48 weeks in total with a 12-month follow-up. The primary endpoints were incidence and severity of adverse events (AEs) and objective response rate (ORR; Response Evaluation Criteria in Solid Tumor V.1.1). ORR was assessed in the efficacy population, being all response-evaluable patients who received any administration of VB10.16 and atezolizumab and had at least one post-baseline imaging assessment. RESULTS: Between June 16, 2020, and January 25, 2022, 52 patients received at least one administration of study treatment. Of these, 47 patients had a minimum of one post-baseline tumor assessment. The median follow-up time for survival was 11.7 months. AEs related to VB10.16 were non-serious and mainly mild injection site reactions (9 of 52 patients). There were no signs of new toxicities other than what was already described with atezolizumab. ORR was 19.1% (95% CI 9.1% to 33.3%). Median duration of response was not reached (n.r.) (95% CI 2.2 to n.r.), median progression-free survival was 4.1 months (95% CI 2.1 to 6.2), and median overall survival was 21.3 months (95% CI 8.5 to n.r.). In programmed death-ligand 1 (PD-L1)-positive patients (n=24), ORR was 29.2% (95% CI 12.6 to 51.1). HPV16-specific T-cell responses were analyzed in 36 of 47 patients with an increase observed in 22/36 (61%). CONCLUSIONS: The therapeutic DNA-based vaccine VB10.16 combined with atezolizumab was safe and well tolerated showing a promising clinically meaningful efficacy with durable responses in patients with persistent, r/m HPV16-positive cervical cancer, especially if PD-L1-positive.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory děložního čípku $x farmakoterapie $x virologie $7 D002583
650    _2
$a lidé středního věku $7 D008875
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a lidský papilomavirus 16 $x imunologie $7 D052162
650    _2
$a dospělí $7 D000328
650    12
$a DNA vakcíny $x aplikace a dávkování $x terapeutické užití $7 D019444
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a senioři $7 D000368
650    _2
$a infekce papilomavirem $x virologie $x imunologie $x komplikace $7 D030361
650    _2
$a vakcíny proti papilomavirům $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D053918
650    _2
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Zikan, Michal $u Department of Obstetrics and Gynecology, Bulovka University Hospital Na Bulovce Budinova 67/2, Prague, Czech Republic
700    1_
$a Forget, Frédéric $u Center hospital de l'Ardenne, Libramont, Belgium
700    1_
$a Denys, Hannelore G $u Medical Oncology, University Hospital Ghent, Gent, Flanders, Belgium
700    1_
$a Baurain, Jean-Francois $u University Clinic Saint-Luc, Bruxelles, Belgium
700    1_
$a Rob, Lukas $u University Hospital Kralovske Vinohrady, Praha, Czech Republic
700    1_
$a Woelber, Linn $u Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Blecharz, Pawel $u Gynecologic Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw Krakow Branch, Krakow, Poland
700    1_
$a Bidzinski, Mariusz $u Gynecologic Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warzawa, Poland
700    1_
$a Chovanec, Josef $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Marmé, Frederik $u Department of Gynecology and Obstetrics, University Hospital Mannheim, Mannheim, Germany
700    1_
$a Link, Theresa $u Department of Gynecology and Obstetrics, Medical Faculty, Dresden, Germany $u Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany
700    1_
$a Dannecker, Christian $u Gynecology and Obstetrics, Faculty of Medicine, University of Augsburg, Augsburg, Germany
700    1_
$a Rosholm, Anders $u Nykode Therapeutics ASA, Oslo, Oslo, Norway
700    1_
$a Berg, Kaja C G $u Nykode Therapeutics ASA, Oslo, Oslo, Norway
700    1_
$a Oliveri, Roberto S $u Nykode Therapeutics ASA, Oslo, Oslo, Norway
700    1_
$a Lindemann, Kristina $u Department of gynecological oncology, Oslo University Hospital, Oslo, Norway klinde@ous-hf.no $u Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000221620175
710    2_
$a VB C-02 investigators
710    2_
$a VB C-02 study
773    0_
$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 13, č. 1 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39773564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135459 $b ABA008
999    __
$a ok $b bmc $g 2311589 $s 1247403
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 13 $c 1 $e 20250107 $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options